Boundless Bio (BOLD) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Boundless Bio (BOLD) has outperformed XBiotech (XBIT) over the past year, gaining 105.3% versus a loss of 24.1%. Boundless Bio is the larger company by market cap ($54.8 million vs $52.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | XBIT |
|---|---|---|
| Share price | $2.32 | $1.73 |
| Market cap | $54.78M | $52.74M |
| 1-day change | -2.52% | +2.98% |
| YTD return | +93.33% | -27.62% |
| 1-year return | +105.31% | -24.12% |
| 5-year return | — | -86.48% |
| Forward P/E | — | 13.31 |
| EPS (TTM) | $-2.46 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-58.20M | $-45.54M |
| 52-week high | $3.16 | $2.73 |
| 52-week low | $0.961 | $1.61 |
| Distance from 52-week high | -26.68% | -36.63% |
| Analyst consensus | none | — |
| Avg. price target upside | +72.41% | — |
| Average volume | 131.34K | 64.77K |
| Shares outstanding | 23.61M | 30.49M |
| Employees | 28 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed XBIT by 129.4 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
BOLD vs XBIT FAQ
Which is bigger, Boundless Bio or XBiotech?
Boundless Bio (BOLD) is larger, with a market capitalization of $54.78M compared with $52.74M for XBiotech (XBIT).
Which stock has performed better over the past year, BOLD or XBIT?
BOLD returned +105.31% over the past 12 months, compared with -24.12% for XBIT (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.